Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-952 PET Imaging in PSP and AD
NCT03080051Phase 1Completed
- Sponsor
- Molecular NeuroImaging
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]MNI-952 in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), sponsored by Molecular NeuroImaging. Primary endpoint: Regional [18F]MNI-952 binding/uptake at 1 year. Started Aug 2016; status: completed.
02
Drugs
[18F]MNI-952
03
Conditions
Alzheimer's disease (AD)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03080051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080051.